; and (II) other information determined appropriate by the Secretary for purposes of enabling such individual to make an informed decision with respect to the effects of using such benefits or such alternative methods to purchase such drug; and (ii) in the case that such individual purchases such drug using such alternative methods, reports to such sponsor or such organization the amount such individual paid for such drug using such alternative methods. (B) Definition For purposes of this paragraph, the term applicable pharmacy means, with respect to a PDP sponsor of a prescription drug plan and a Medicare Advantage organization offering an MA–PD plan, a pharmacy with which such sponsor or such organization contracts with under such prescription drug plan or such MA–PD plan or that is otherwise an in-network pharmacy under such prescription drug plan or such MA–PD plan. (3) Determination A determination specified in this paragraph is a determination by the Secretary that a prohibition or penalty described in paragraph (1) is being used by a PDP sponsor of a prescription drug plan or a Medicare Advantage organization offering an MA–PD plan with respect to such prescription drug plan or MA–PD plan. . (c) Study of prevalence of pharmacy provision of information prohibitions Not later than 1 year after the date of the enactment of this Act, the Secretary of Health and Human Services (in this section referred to as the Secretary ) shall conduct a study and submit to Congress a report on the prevalence of prohibitions by— (1) group health plans and health insurance issuers (as such terms are defined in section 2791 of the Public Health Service Act ( 42 U.S.C. 300gg–91 )); and (2) MA organizations offering MA–PD plans and sponsors of prescription drug plans; on pharmacies from disclosing alternative prices of a drug to an individual purchasing such drug at such pharmacy using benefits under such group health plan, such health insurance coverage, such MA–PD plan, or such prescription drug plan (as applicable).